Protective effect of inhaled iloprost on exercise-induced bronchoconstriction Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004
Protective effect of inhaled glucocorticosteroids on COPD model. Source: Virtual Congress 2020 – Mechanistic insight into lung injury and repair Year: 2020
Pharmacodynamic effects of nebulised bronchodilator combinations Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Protective effect of inhaled iloprost on specific bronchial challenge in aspirin-sensitive asthma Source: Eur Respir J 2002; 20: Suppl. 38, 471s Year: 2002
Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Effect of antileukotriene therapy on methacholine challenge test in patients with mild asthma Source: Eur Respir J 2004; 24: Suppl. 48, 587s Year: 2004
Effect of long-acting ß-agonist on bronchodilator response in children with asthma Source: Eur Respir J, 56 (3) 1902010; 10.1183/13993003.02010-2019 Year: 2020
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol Source: Eur Respir J 2001; 17: 368-373 Year: 2001
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Protective effect of hyaluronic acid on the effects of bronchoprovocation with methacholine challange in asthmatics Source: Eur Respir J 2004; 24: Suppl. 48, 442s Year: 2004
Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018 Year: 2019
Low systemic exposure of NVA237, an inhaled once-daily anticholinergic bronchodilator, in healthy humans Source: Eur Respir J 2006; 28: Suppl. 50, 661s Year: 2006
Safety and efficacy of inhaled mannitol as a bronchial provocation test in children Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
High doses of inhaled formoterol have less systemic effect in asthmatic children than high doses of inhaled terbutaline Source: Eur Respir J 2003; 22: Suppl. 45, 534s Year: 2003
Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids? Source: Annual Congress 2007 - Treatment of COPD Year: 2007
Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment Source: Eur Respir J 2001; 18: Suppl. 33, 103s Year: 2001
The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004
RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016
The anti-tussive effects of an inhaled LABA are maintained after chronic treatment Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018